Cipher Pharmaceuticals Inc. functions as a specialized pharmaceutical company based in Canada. The firm markets a diverse portfolio of therapies, including Epuris (CIP-ISOTRETINOIN), an isotretinoin formulation specifically developed for addressing severe acne; Ozenoxacin, prescribed for the management of impetigo in both adult and pediatric populations; Actikerall, indicated for treating palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream designed to diminish unwanted facial hair growth in women; BRINAVESS, a treatment aimed at restoring sinus rhythm in adults; and AGGRASTAT, an anti-platelet medication administered intravenously. Furthermore, Cipher holds licenses for several products, which encompass CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a fenofibrate-based formulation used to treat hyperlipidemia, a disorder characterized by high cholesterol; and Conzip/Durela (CIP-Tramadol), a tramadol formulation intended for alleviating moderate to moderately severe pain. Looking ahead, the company's development pipeline features several innovative compounds: Trevyent, a vasodilatory prostacyclin analogue targeting pulmonary arterial hypertension; CF-101, which is being explored for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for the treatment of onychomycosis; and DTR-001, a cream under development for tattoo removal. Cipher Pharmaceuticals Inc. was established in the year 2000, with its primary operations located in Oakville, Canada.
—
Cipher Pharmaceuticals Inc. functions as a specialized pharmaceutical company based in Canada. The firm markets a diverse portfolio of therapies, including Epuris (CIP-ISOTRETINOIN), an isotretinoin formulation specifically developed for addressing severe acne; Ozenoxacin, prescribed for the management of impetigo in both adult and pediatric populations; Actikerall, indicated for treating palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream designed to diminish unwanted facial hair growth in women; BRINAVESS, a treatment aimed at restoring sinus rhythm in adults; and AGGRASTAT, an anti-platelet medication administered intravenously. Furthermore, Cipher holds licenses for several products, which encompass CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a fenofibrate-based formulation used to treat hyperlipidemia, a disorder characterized by high cholesterol; and Conzip/Durela (CIP-Tramadol), a tramadol formulation intended for alleviating moderate to moderately severe pain. Looking ahead, the company's development pipeline features several innovative compounds: Trevyent, a vasodilatory prostacyclin analogue targeting pulmonary arterial hypertension; CF-101, which is being explored for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for the treatment of onychomycosis; and DTR-001, a cream under development for tattoo removal. Cipher Pharmaceuticals Inc. was established in the year 2000, with its primary operations located in Oakville, Canada.
—
Daily adjusted close
Cipher Pharmaceuticals Inc. functions as a specialized pharmaceutical company based in Canada. The firm markets a diverse portfolio of therapies, including Epuris (CIP-ISOTRETINOIN), an isotretinoin formulation specifically developed for addressing severe acne; Ozenoxacin, prescribed for the management of impetigo in both adult and pediatric populations; Actikerall, indicated for treating palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream designed to diminish unwanted facial hair growth in women; BRINAVESS, a treatment aimed at restoring sinus rhythm in adults; and AGGRASTAT, an anti-platelet medication administered intravenously. Furthermore, Cipher holds licenses for several products, which encompass CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a fenofibrate-based formulation used to treat hyperlipidemia, a disorder characterized by high cholesterol; and Conzip/Durela (CIP-Tramadol), a tramadol formulation intended for alleviating moderate to moderately severe pain. Looking ahead, the company's development pipeline features several innovative compounds: Trevyent, a vasodilatory prostacyclin analogue targeting pulmonary arterial hypertension; CF-101, which is being explored for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for the treatment of onychomycosis; and DTR-001, a cream under development for tattoo removal. Cipher Pharmaceuticals Inc. was established in the year 2000, with its primary operations located in Oakville, Canada.